keynote trials show pembrolizumab benefited patients with advanced small cell lung cancer
Published 5 years ago • 222 plays • Length 6:32Download video MP4
Download video MP3
Similar videos
-
0:51
pembrolizumab increases long-term survival in patients with advanced nsclc
-
3:10
pembrolizumab new option for firstline treatment of advanced lung cancer with high pdl-1 expression
-
4:20
keynote-604: pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-sta...
-
7:13
first-line pembrolizumab plus chemotherapy for patients with advanced squamous nsclc: 3-year fol...
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
1:14
keynote-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy
-
4:57
keynote-024 shows prolonged nsclc survival benefit with pembrolizumab | julie brahmer
-
7:50
keynote-598: pembrolizumab with ipilimumab or placebo in patients with untreated metastatic nsclc
-
3:32
keynote-028 and keynote-158: pembrolizumab as treatment for advanced sclc after two or more line...
-
3:52
keynote 10: pembrolizumab vs docetaxel for nsclc
-
2:53
keynote-407: pembrolizumab plus chemo improves os and pfs in nsclc
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
3:31
the keynote-024 precedent for advanced-nsclc treatment
-
3:07
the keynote-001 trial: a breakthrough for pembrolizumab
-
2:11
pembrolizumab works better than chemotherapy alone as initial treatment for nsclc
-
1:02
pembrolizumab monotherapy for nsclc: keynote-024 update
-
8:19
keynote trial data: pembrolizumab’s role in nsclc
-
1:18
dr. reck on the safety of pembrolizumab in keynote-024 in metastatic nsclc
-
2:30
association between ttmb and clinical outcomes with pembrolizumab alone in pd-l1-positive advanc...